All of our products are prescription-only medicines (POM). If more information is required, please refer to the local SPC or PIL.
ABILIFY contains the active substance aripiprazole. It is available in different forms (tablets, oral solution and a solution for injection).
ABILIFY is used in the treatment of schizophrenia and moderate to severe manic episodes in Bipolar I Disorder.
Abilify Maintena® (aripiprazole)
Abilify Maintena contains the active substance aripiprazole. It is available as a powder and solvent to be made into a suspension for injection.
It is used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised on treatment with oral aripiprazole.
Samsca contains the active substance tolvaptan. It is available as a tablet.
Samsca is used to treat adults with hyponatraemia (abnormally low levels of sodium in the blood) caused by a condition called ‘syndrome of inappropriate antidiuretic-hormone secretion’ (SIADH).
JINARC contains the active ingredient tolvaptan and it is available as a tablet. It is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease (CKD) stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.
SPRYCEL contains the active substance dasatinib and is available as tablets of various strengths.
It is indicated for the treatment of adults with the following types of leukaemia (cancer of the white blood cells):
- Chronic myeloid leukaemia (CML) in the ‘chronic’ phase in newly diagnosed patients who are ‘Philadelphia chromosome positive’ (Ph+).
- CML in ‘chronic’, ‘accelerated’ and ‘blast’ phases. SPRYCEL is used when patients cannot tolerate, or when their disease is not responding to, other treatments including imatinib.
- Ph+ acute lymphoblastic leukaemia (ALL), where lymphocytes multiply too quickly, or in ‘lymphoid blast’ CML. SPRYCEL is used when patients cannot tolerate, or when their disease is not responding to, other treatments.
The medicine can only be obtained with a prescription.
The Marketing Authorisation Holder of the drug is Bristol-Myers Squibb Pharma EEIG.
Pletal contains the active substance cilostazol. It is available as a tablet.
Pletal is indicated for the improvement of maximal and pain-free walking distances in patients with intermittent claudication, who do not have rest pain and who do not have evidence of peripheral tissue necrosis (peripheral arterial disease Fontaine stage II).
Please refer to local country sites as Pletal is not available in some countries.
Medical device for leukocyte apheresis.
Adacolumn is a medical device for the treatment of active inflammatory bowel disease (IBD). The treatment works through selective adsorption of leukocytes (selectively granulocytes and monocytes/macrophages) from the blood.
UBIT® (100mg film-coated tablet)
This medicinal product is only for diagnostic use.
UBIT 100 mg film-coated tablet is for the in vivo diagnosis of gastroduodenal Helicobacter pylori infection. Each tablet contains the active ingredient 100 mg of 13C-urea
* Please note that UBIT is not centrally approved in Europe and only available in some countries
For more information about Otsuka’s global portfolio, please visit our global website.
For information on products that are currently in the pipeline, please visit the Otsuka Holdings Co., Ltd. website.